SUPPLEMENTARY MATERIAL

Supplementary Material and methods	
Supplementary Tables	
Supplementary Figure legends	

SUPPLEMENTARY MATERIAL AND METHODS

Study participants

A total of 82 early RA patients fulfilling the 2010 ACR/EULAR classification criteria (1) participated in this study. RA patients were recruited at disease onset from the early arthritic clinic of the Department of Rheumatology at Hospital Universitario Central de Asturias (HUCA), and therefore were not exposed to disease-modifying antirheumatic drugs (DMARDs) at the time of sampling. A complete clinical examination, including Disease Activity Score 28-joints (DAS28), Simplified Disease Activity Index (SDAI) and Health Assessment Questionnaire (HAQ) calculations, was carried out during the clinical appointment.

Subjects with clinically-suspect arthralgia (CSA) (n=14) were recruited from the same clinic if they met at least four criteria of the EULAR definition of arthralgia suspicious for progression to RA (2). A group of 96 healthy controls (HC) (70 women/26 men, mean age 60.00 (range 27.00-83.50) years) were recruited among age- and sex-matched healthy individuals from the same population.

A group (n=42) of long-lasting, established RA patients (LRA), also fulfilling 2010 ACR/EULAR classification criteria (1) but with more than 6 months of disease duration (median 6.76 years), was recruited from the same department as a validation cohort.

A fasting blood sample was collected from all individuals by venepuncture. Serum samples were immediately transferred to the laboratory and processed within less than 2 hours. Serum samples were stored at -80°C until experimental procedures. Conventional blood biochemical (including CRP and ESR measurements) and lipid analyses were performed in all individuals. The presence of traditional CV risk factors (dyslipemia, hypertension, obesity, diabetes and smoking history) based on national guidelines was obtained from the medical records. Body measurements such as weight, height and waist circumference were performed at recruitment. CV risk was assessed using the mSCORE (3) and patients were grouped in risk categories (0-5: low and moderate; and >5: high and very high) according to the ESC consensus (4).

The study was approved by the local institutional review board (Comité de Ética de Investigación Clínica del Principado de Asturias) in compliance with the Declaration of

Helsinki (reference CEImPA 2021.126). All study subjects gave written informed consent.

Vascular imaging and functional assessments

Doppler ultrasound assessment was performed in the sonography laboratory (Department of Neurology, HUCA) by an experienced user blinded to the status of the study participants. All measures were carried out online in B-mode using a Toshiba Aplio XG device (Toshiba American Medical Systems) with software version 5.1. The carotid intima-media thickness (cIMT) was bilaterally measured (left and right common carotid arteries), according to the "Mannheim Carotid Intima-Media Thickness Consensus (2004-2006)" (5), and the mean value was used. The reproducibility of the cIMT measurement was 89.0%. Atherosclerotic plaque was defined as a distinct area protruding into the vessel lumen at least 0.5 mm, with 50% greater thickness than the cIMT found in surrounding areas or the presence of a cIMT>1.5 mm (5). Plaque prevalence was considered as the frequency of patients exhibiting at least one plaque according to the previous consensus definition. Plaque vulnerability was assessed by the ultrasound appearance of the plaques, and these were classified as "low" or "high" risk (6).

Vascular functionality was quantified by evaluating the diameter changes of the common carotid during an entire cardiac cycle. To this end, stiffness parameters (vascular strain and stiffness, vascular distensibility and pressure-strain elastic modulus (PSEM)) were calculated (7,8).

Quantification of antibodies against HDL particles

Levels of antibodies against HDL or ApoA1 were measured in serum samples by in-house enzyme-linked immunosorbent assays (ELISA).

Anti-HDL levels (both IgG and IgM) were measured as previously described (9) with slight modifications. First, Polysorp (Nunc) plates were half-coated overnight at room temperature with 20 µg/ml human HDL-cholesterol (Sigma) in 70% ethanol (test half) or ethanol alone (control half). The plates were blocked with 1% bovine serum albumin (BSA) in phosphate buffer saline (PBS) (pH 7.4) for 1 hour at 37° C and then washed with PBS. Next, standard curves (pooled sera diluted 1:16 to 1:512), diluted samples (1:50) were prepared in 0.1% BSA PBS and incubated for 2 h at room temperature under

shacking. Unbound antibodies were removed by repeating the washing step. Alkaline phosphatase-conjugated anti-human IgG (1:1000) or IgM (1:500) (Immunostep) in 1% BSA tris buffer saline (TBS) were added and incubated for 1h. Finally, the plate was washed twice with TBS and 1 mg/ml p-nitrophenylphosphate (Sigma) diluted in dietanolamine buffer (pH 9.8) was added to the wells. Absorbance at 405 nm was recorded and the signal from the control half of the plate was subtracted to that of the test half. Anti-HDL Arbitrary Units (AU) were calculated for each sample according to the standard curves. Our assay had a within-run imprecision (coefficient of variation) of 9.81%, and a between-run coefficient of variation of 11%.

The protocol for anti-ApoA1 antibodies was adapted from the previous one, according to Frias et al. (10). Briefly, Polysorp plates were half-coated with 10 μ g/ml human Apolipoprotein A1 (Sigma) in 70% ethanol (test half) or 70% ethanol alone (control half) for 2h at 37° C. Plates were blocked as previously described and incubated with standards and samples (diluted 1:100) for 2h at room temperature under shacking. Unbound antibodies were removed by washing with TBS and alkaline phosphatase-conjugated antihuman IgG (1:1000) or IgM (1:1000) were added in 1% BSA tris buffer saline (TBS) and incubated for 1h. The washing step was repeated, and substrate was added as previously described. Intra- and inter-assay coefficients of variation for anti-ApoA1 were 7.50% and 9.80%, respectively.

Assessment of PON1 activity

PON1 activity was quantified in serum samples by means of an enzymatic assay according to Eckerson et al. (11) with slight modifications, as previously reported (9). In brief, 7.5 μl of serum samples were incubated with 300 μl of 1 mM paraoxon (Sigma Aldrich) freshly prepared in 50 mM glycine buffer (with 1 mM CaCl₂, pH 10.5) in 96-well Maxisorp plates (Nunc) for 20 minutes at 37° C. The production of p-nitrophenol was monitored at 405 nm using a spectrophotometer. A unit (U) of PON1 activity was expressed as p-nitrophenol μmoles formed per minute and per ml of serum. Negative and quality controls were included in each plate to correct for inter-assay variations. Interand intra-assay coefficients of variation were 9.91% and 6.12%, respectively.

Lipoprotein characterization

An advanced lipoprotein characterization by means of the H-NMR-based Liposcale test (12) was performed. This protocol allowed the assessment of lipid content (cholesterol and triglycerides) of VLDL, IDL, LDL and HDL as well as the particle number and size (diameter) of VLDL LDL and HDL and their subclasses (small, medium and large). To this end, serum samples were diluted with deuterated water and 50 mM pH 7.4 phosphate buffer solution before H-NMR analysis. Then, H-NMR spectra were recorded at 310 K on a Bruker Advance III 600 spectrometer operating at a proton frequency of 600.20 MHz. Particle concentration and the diffusion coefficients were obtained from the measured amplitudes and attenuation of their spectroscopically distinct lipid methyl group NMR signals, using the 2D diffusion-ordered 1H NMR spectroscopy (DSTE) pulse as previously described (12).

Measurement of serum cytokine levels

The serum levels of IFN α and MIP1 α were quantified using a Cytometric Bead Array Flex Set (BD) in a BD FACS Canto II flow cytometer using FCAP Array v.1.0.1, following the manufacturer's instructions. The detection limits were 1.25 pg/ml and 0.6 pg/ml, respectively.

IL-6, TNF, IFN γ , IL-1 β , IL-23, IL-12 and IL-8 serum levels were assessed using a predefined multiplex assay (Human Inflmammation Panel 1, LEGENDplex, BioLegend) using the same device, according to the protocol provided by the manufacturer. The detection limits were 1.5 pg/ml, 0.9 pg/ml, 1.3 pg/ml, 1.5 pg/ml, 1.8 pg/ml, 2.0 pg/ml and 2.0 pg/ml, respectively.

Proteomic analysis

A pre-defined panel of 92 proteins related to CV (CV Panel II) was measured in serum samples using the Proximity Extension Assay proprietary test from Olink (Olink Bioscience, Sweden) (13).

Statistical analyses

Continuous variables were expressed as median (interquartile range) or mean±standard deviation, whereas categorical variables were summarized as n(%).

Differences among groups were evaluated by one-way ANOVA, Mann-Withney U, Kruskal-Wallis or $\chi 2$ tests, as appropriate. Correlations were assessed by Spearman ranks' tests. Corrections for multiple comparison tests were performed by Dunn-Bonferroni or by Benjamini-Hochberg procedure (14), as required. The associations between antibody levels and atherosclerosis occurrence were analysed by multiple logistic regression. Due to the overdispersion of the number of plaques, negative binomial regression models were used when studied as an outcome variable. Adjusted OR and 95% confidence intervals (CI) were calculated. The discrimination ability for subclinical CV disease was assessed using the area under the receiver operating characteristic curve (AUC ROC). In order to add the antibody levels to the mSCORE algorithm, categories were defined from the distribution of the antibody levels observed in the HC population using tertiles as cut-offs and a score was given as follows: 0 to T1: +0, T1 to T2: +1, and T2 to T3: +2 points. These points were added to the mSCORE values (mSCORE + anti-HDL).

The performance of the classification of mSCORE and mSCORE + antibodies was analysed by classification measures (sensitivity, specificity, % patients correctly classified and likelihood ratios), Matthews' correlation coefficient, goodness of fit (Hosmer–Lemeshow test) and the Youden index to determine the optimal cut-offs (threshold points with maximum accuracy). Differences in the AUC ROC values were compared by the De Jong statistic.

Proteomic data were evaluated by functional and pathway enrichment analyses using ShinyGo 0.76 (15) and KEGG platforms (16) to identify biological pathways. Protein-protein interactions were assessed by the STRING database (17). To investigate whether common transcriptional regulatory networks may underlie the protein networks, the TRRUST database (18) was used to predict transcription factors that regulate hub genes.

A p-value <0.050 was considered as statistically significant. Statistical analyses were carried out under SPSS v. 27, R v.4.1.3 and GraphPad Prism 8.0.

REFERENCES

- 1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010;69:1580–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20699241.
- 2. Steenbergen HW van, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2017;76:491–496. Available at: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-209846.
- 3. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017;76:17–28. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27697765.
- 4. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal* 2016;37:2315–2381.
- 5. Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim Carotid Intima-Media Thickness Consensus (2004–2006). *Cerebrovascular Diseases* 2007;23:75–80. Available at: https://www.karger.com/Article/FullText/97034.
- 6. Picano E, Paterni M. Ultrasound Tissue Characterization of Vulnerable Atherosclerotic Plaque. *International Journal of Molecular Sciences* 2015;16:10121–10133. Available at: http://www.mdpi.com/1422-0067/16/5/10121.
- 7. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante G e. E. Clinical applications of arterial stiffness; definitions and reference values. *American Journal of Hypertension* 2002;15:426–444. Available at: https://academic.oup.com/ajh/article-lookup/doi/10.1016/S0895-7061(01)02319-6.
- 8. Zardi EM, Sambataro G, Basta F, Margiotta DPE, Afeltra AMV. Subclinical Carotid Atherosclerosis in Elderly Patients with Primary Sjögren Syndrome: A Duplex Doppler Sonographic Study. *International Journal of Immunopathology and Pharmacology* 2014;27:645–651. Available at: http://journals.sagepub.com/doi/10.1177/039463201402700422.
- 9. Rodríguez-Carrio J, Alperi-López M, López P, Ballina-García FJ, Abal F, Suárez A. Antibodies to high-density lipoproteins are associated with inflammation and cardiovascular disease in rheumatoid arthritis patients. *Translational Research* 2015;166:529–539. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1931524415002522.
- 10. Frias MA, Virzi J, Batuca J, Pagano S, Satta N, Delgado Alves J, et al. ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. *Journal of Immunological Methods* 2019;469:33–41. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0022175919300407.
- 11. Eckerson HW, Wyte CM, Du BN la. The human serum paraoxonase/arylesterase polymorphism. *Am J Hum Genet* 1983;35:1126–38.

- 12. Mallol R, Amigó N, Rodríguez MA, Heras M, Vinaixa M, Plana N, et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1 H NMR spectroscopy. *Journal of Lipid Research* 2015;56:737–746. Available at: http://www.jlr.org/lookup/doi/10.1194/jlr.D050120.
- 13. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic Acids Research* 2011;39:e102–e102. Available at: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkr424.
- 14. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple testing. *J R Statist Soc B* 1995;57:289–300.
- 15. Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Valencia A, ed. *Bioinformatics* 2020;36:2628–2629. Available at: https://academic.oup.com/bioinformatics/article/36/8/2628/5688742.
- 16. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. *Nucleic Acids Research* 2021;49:D545–D551. Available at: https://academic.oup.com/nar/article/49/D1/D545/5943834.
- 17. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Research* 2021;49:D605–D612. Available at: https://academic.oup.com/nar/article/49/D1/D605/6006194.
- 18. Han H, Cho J-W, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. *Nucleic Acids Research* 2018;46:D380–D386. Available at: http://academic.oup.com/nar/article/46/D1/D380/4566018.

SUPPLEMENTARY TABLES

Supplementary Table 1: Demographic, clinical and subclinical atherosclerosis assessments in RA and CSA. Demographic, clinical features, traditional CV risk factors and subclinical atherosclerosis features of RA patients and CSA individuals were summarized. Variables were expressed as median (interquartile range), mean±SD or n(%), unless otherwise stated, according to the distribution of the variables.

	CSA n=14	RA n=82
Age (years), mean (range)	49.28	58.51
age (years), mean (range)	(30.00-62.33)	(30.33-83.67)
Gender (female/male)	14/0	66/16
Clinical features		
Ouration of symptoms (weeks)	24.00 (40.00)	20.00 (22.00)
Morning stiffness (minutes)	30.00 (50.00)	60.00 (80.0)
Tender joint count	3.00 (3.00)	8.00 (7.00)
Swollen joint count	0.00 (1.00)	6.00 (5.00)
ESR (mm/h)	7.50 (8.84)	24.00 (27.00)
CRP (mg/dl)	0.15 (0.30)	0.80 (2.20)
Patient global assessment (VAS 0-	20.00 (50.00)	70.00 (25.00)
100)	30.00 (50.00)	70.00 (25.00)
Pain assessment (VAS 0-10)	5.00 (5.00)	7.00 (2.00)
DAS28		5.40 (1.78)
SDAI		24.22 (16.90)
HAQ	0.55 (0.60)	1.11 (1.00)
Fatigue (VAS 0-10)	4.50 (5.00)	5.00 (7.00)
RF+, n(%)	8 (66.6)	57 (69.5)
ACPA+, n(%)	7 (58.3)	56 (68.2)
Fraditional CV risk factors		
Hypertension, n(%)	1 (12.5)	28 (34.1)
Diabetes, n(%)	0 (0.0)	9 (10.9)

Dyslipidemia, n(%)	3 (37.5)	24 (29.2)
Smoking, n(%)	10 (71.4)	31 (27.8)
Obesity (BMI>30 kg/m ²), n(%)	3 (37.5)	33 (40.2)
Waist circumference (cm)	92.00 (16.00)	101.00 (20.00)
Subclinical atherosclerosis (n=92)	n=13	n=77
Plaque presence, n(%)	4 (30.7)	46 (59.7)
Plaque number, mean (range)	0.46 (0-3)	0.96 (0-4)
High-risk plaque, n(%)	0 (0.0)	20 (25.9)
cIMT (mm)	0.58 ± 0.15	0.67 ± 0.10
VS	0.10 ± 0.03	0.10 ± 0.04
VD	0.0055 ± 0.0031	0.0044 ± 0.002
VSf	504.24±286.37	540.04±239.61
PSEM	3.52±2.00	3.83±1.68

Supplementary Table 2: Demographic and parameters of long-lasting, established

RA (**LRA**). Demographic and clinical features of established RA patients recruited as a validation cohort. Variables were expressed as median (interquartile range), mean \pm SD or n(%), unless otherwise stated, according to the distribution of the variables.

	LRA n=42
A co (voors) moon (vonco)	52.58
Age (years), mean (range)	(22.42-71.42)
Gender (female/male)	36/6
Clinical features	
Disease duration, mean (range) (years)	6.76 (0.50 – 30.00)
Tender joint count	2.00 (6.50)
Swollen joint count	1.00 (4.00)
ESR (mm/h)	13.00 (23.00)
CRP (mg/dl)	0.50 (0.95)
Patient global assessment (VAS 0-	45 00 (46 50)
100)	45.00 (46.50)
Pain assessment (VAS 0-10)	5.00 (4.50)
DAS28	3.46 (1.58)
HAQ	1.00 (1.31)
RF+, n(%)	19 (45.2)
ACPA+, n(%)	23 (54.7)
Traditional CV risk factors	
Hypertension, n(%)	15 (35.7)
Diabetes, n(%)	2 (4.7)
Dyslipidemia, n(%)	16 (38.0)
Smoking, n(%)	15 (35.7)
Obesity (BMI>30 kg/m ²), n(%)	10 (23.8)
Treatments, n(%)	
Glucocorticoids	25 (59.5)
Methotrexate	34 (80.9)
TNF blockers	18 (42.8)

IL-6 blockers	3 (19.0)
Leflunomide	4 (9.5)

Supplementary Table 3: Lipoprotein characterization by H-NMR. An advanced characterization of the lipoprotein profile was performed by H-NMR. Differences were assessed by a one-way ANOVA test. Variables were summarized as mean±SD.

	нс	CSA	RA	p-value
Lipoprotein content				
VLDL-C (mg/dl)	10.39±7.06	13.07±7.64	17.50±12.78	0.116
IDL-C (mg/dl)	8.63±4.22	9.43 ± 4.42	11.74±5.13	0.089
LDL-C (mg/dl)	134.78±25.16	133.51±26.67	136.62±30.79	0.739
HDL-C (mg/dl)	58.33±12.01	58.70±11.90	53.69±12.53	0.144
VLDL-TG (mg/dl)	56.95±27.18	60.90±32.89	78.94±63.97	0.222
IDL-TG (mg/dl)	9.91±3.92	10.04±3.49	12.07±3.77	0.055
LDL-TG (mg/dl)	13.12±3.64	15.67±4.34	17.79±5.44	0.079
HDL-TG (mg/dl)	15.57±4.01	15.28±5.99	16.63±4.81	0.277
Lipoprotein subclase	s distribution			
VLDL-P (nmol/l)	40.99±21.02	44.20±24.48	57.90±43.04	0.208
Large VLDL-P	1.18 ± 0.80	1.14 ± 0.51	1.47 ± 0.80	0.222
Medium VLDL-P	3.28 ± 2.20	4.66 ± 2.34	5.79±7.21	0.076
Small VLDL-P	37.06±20.19	38.36±21.84	50.63±36.11	0.207
LDL-P (nmol/l)	1377.57±251.19	1339.99±283.15	1400.82±321.86	0.655
Large LDL-P	188.88±37.76	188.17±33.89	189.20±37.76	0.871
Medium LDL-P	386.18±98.42	408.57±111.69	422.90±140.32	0.565
Small LDL-P	779.17±151.84	743.23±193.69	788.71±206.98	0.584
HDL-P (µmol/l)	29.08±4.60	29.51±4.36	27.78±5.25	0.179
Large HDL-P	0.25±0.03	0.26 ± 0.03	0.27 ± 0.04	0.510
Medium HDL-P	9.17±1.80	9.97±1.52	9.54±1.59	0.495
Small HDL-P	18.90±3.21	19.27±3.33	17.96±4.31	0.247
Lipoprotein size				
VLDL diameter (nm)	41.95±0.56	42.18±0.34	42.03±0.42	0.133
LDL diameter (nm)	21.00±0.27	21.11±0.35	21.03±0.38	0.514
HDL diameter (nm)	8.11±0.06	8.27±0.06	8.29 ± 0.10	0.512

Supplementary Table 4: PON1 activity and lipoprotein profile. Associations between serum PON1 activity and HDL features (particle number and size) were analysed by Spearman ranks' test in RA patients. Those reaching statistical significance are highlighted in bold.

	PON1
Particle number	
HDL-P (mmol/l)	r=0.275 p=0.016
Large	r=0.046 p=0.682
Medium	r=0.080 p=0.475
Small	r=0.314 p=0.004
Particle diameter (mm)	
HDL-Z	r=-0.276 p=0.012

Supplementary Table 5: Associations between antibodies against HDL and traditional CV risk factors. Associations between levels of antibodies against HDL or ApoA1 and traditional CV risk factors were analysed by Spearman's rank tests or Mann-Withney U tests in CSA and RA groups. Coefficients (r) and p-values, or p-values for the difference between groups are shown.

CSA]	RA		
	Anti-HDL IgG	Anti-HDL IgM	Anti-ApoA1 IgG	Anti-ApoA1 IgM	Anti-HDL IgG	Anti-HDL IgM	Anti-ApoA1 IgG	Anti-ApoA1 IgM
Demographic para	imeters							
Age	r=-0.095 p=0.748	r=-0.354 p=0.215	r=-0.002 p=0.994	r=0.374 p=0.185	r=-0.028 p=0.804	r=-0.088 p=0.434	r=0.150 p=0.178	r=0.006 p=0.954
Sex					p=0.377	p=0.925	p=0.967	p=0.208
Traditional CV ris	k factors							
Hypertension	p=0.999	p=0.571	p=0.714	p=0.286	p=0.728	p=0.910	p=0.273	p=0.220
Smoking	p=0.188	p=0.733	p=0.539	p=0.839	p=0.850	p=0.059	p=0.999	p=0.059
Dyslipemia	p=0.368	p=0.368	p=0.659	p=0.659	p=0.891	p=0.659	p=0.450	p=0.453
Diabetes					p=0.269	p=0.953	p=0.362	p=0.045
Obesity	p=0.263	p=0.370	p=0.172	p=0.105	p=0.393	p=0.786	p=0.786	p=0.786

Waist	r=0.321	r=0.524	r=0.332	r=0.182	r=0.009	r=-0.002	r=-0.114	r=-0.180
circumference	p=0.482	p=0.227	p=0.467	p=0.696	p=0.941	p=0.985	p=0.350	p=0.139

Supplementary Table 6: Associations between antibodies against HDL and serum cytokines. Associations between levels of antibodies against HDL or ApoA1 and levels of serum cytokines were analysed by Spearman's rank tests in CSA and RA groups. Coefficients (r) and p-values are shown. Those reaching statistical significance are highlighted in bold.

	CSA			RA				
	Anti-HDL	Anti-HDL	Anti-ApoA1	Anti-ApoA1	Anti-HDL	Anti-HDL	Anti-ApoA1	Anti-ApoA1
	IgG	IgM	IgG	IgM	IgG	IgM	IgG	IgM
IFNa	r=0.018	r=0.120	r=-0.167	r=0.195	r=0.227	r=0.274	r=0.072	r=0.111
	p=0.950	p=0.683	p=0.568	p=0.504	p=0.040	p=0.013	p=0.523	p=0.320
MIP-1a	r=0.236	r=0.111	r=0.204	r=0.313	r=0.257	r=0.357	r=0.194	r=0.470
	p=0.416	p=0.707	p=0.483	p=0.276	p=0.020	p<0.001	p=0.081	p<0.001
IL-6	r=0.078	r=-0.053	r=0.308	r=0.192	r=0.354	r=0.243	r=0.277	r=0.074
	p=0.790	p=0.858	p=0.283	p=0.512	p=0.001	p=0.028	p=0.012	p=0.511
TNF	r=0.194	r=-0.026	r=0.198	r=0.271	r=0.055	r=0.035	r=0.197	r=0.259
	p=0.507	p=0.929	p=0.497	p=0.349	p=0.624	p=0.752	p=0.076	p=0.019
IFNg	r=0.194	r=-0.281	r=0.146	r=-0.173	r=0.346	r=0.194	r=0.154	r=0.201
	p=0.507	p=0.331	p=0.618	p=0.554	p=0.001	p=0.081	p=0.167	p=0.080
IL-1b	r=0.310	r=-0.024	r=0.209	r=0.400	r=0.098	r=0.099	r=0.230	r=0.205
	p=0.280	p=0.934	p=0.474	p=0.156	p=0.379	p=0.375	p=0.037	p=0.065
IL-23	r=0.129	r=0.229	r=0.108	r=0.488	r=0.153	r=0.147	r=0.158	r=0.208
	p=0.661	p=0.431	p=0.714	p=0.076	p=0.169	p=0.189	p=0.158	p=0.005
IL-12	r=0.006	r=0.159	r=0.044	r=0.620	r=0.030	r=0.137	r=0.121	r=0.318
	p=0.985	p=0.588	p=0.881	p=0.018	p=0.790	p=0.220	p=0.281	p=0.004
IL-8	r=0.184	r=0.183	r=0.361	r=0.060	r=0.334	r=0.472	r=0.410	r=0.075
	p=0.529	p=0.531	p=0.205	p=0.839	p=0.002	p=0.001	p=0.001	p=0.503

Supplementary Table 7: IgG anti-HDL as predictor of atherosclerosis plaque burden in RA. The role of IgG anti-HDL levels as predictor of atherosclerosis plaque burden in early RA patients was analysed by univariate and multivariate negative binomial regression models. The number of atherosclerosis plaques was entered as the dependent variable.

	RR	95% CI	p-value
Univariate			
IgG anti-HDL, per unit	1.001	1.000 - 1.001	0.023
Multivariate			
IgG anti-HDL, per unit	1.001	1.000 – 1.001	0.020
Sex, women	0.943	0.509 – 1.748	0.852
Age, per year	1.019	0.992 – 1.048	0.171
Dislipemia, yes	0.742	0.435 – 1.266	0.274
Diabetes, yes	0.001	0.000 - 0.001	0.999
Hypertension, yes	1.267	0.548 - 2.930	0.581
Smoking, yes	1.647	0.370 - 2.367.	0.125

Obesity, yes	1.341	0.727 – 2.471	0.348
--------------	-------	---------------	-------

Supplementary Table 8: Associations between antibodies against HDL and serum proteome features. Associations between levels of antibodies against HDL or ApoA1 and levels of serum proteome features were analysed by Spearman's rank tests in RA patients. Coefficients (r) and p-values (univariate analyses, first column) and FDR-corrected (FDR=0.1) p-values (Benjamini-Hochberg, second column) are shown. Those reaching statistical significance in the latter are highlighted in bold.

	Anti-HD	L IgG	Anti-HI	Anti-HDL IgM		A1 IgG	Anti-ApoA1 IgM	
	r, p univ	p BH	r, p univ	p BH	r, p univ	p BH	r, p univ	p BH
BMP6	r=0.176 p=0.148	p=0.328	r=-0.203 p=0.094	p=0.305	r=-0.066 p=0.589	p=0.949	r=-0.221 p=0.068	p=0.687
ANGPT1	r=-0.293 p=0.010	p=0.053	r=-0.282 p=0.019	p=0.130	r=-0.248 p=0.040	p=0.279	r=-0.186 p=0.126	p=0.764
ADM	r=0.213 p=0.079	p=0.217	r=0.033 p=0.789	p=0.908	r=-0.104 p=0.397	p=0.903	r=-0.045 p=0.716	p=0.968
CD40L	r=0.094 p=0.440	p=0.563	r=-0.157 p=0.197	p=0.481	r=0.004 p=0.972	p=0.993	r=-0.005 p=0.967	p=0.988
SLAMF7	r=0.393 p<0.01	p=0.053	r=0.239 p=0.048	p=0.218	r=0.329 p=0.006	p=0.085	r=-0.045 p=0.713	p=0.968
PGF	r=0.330 p=0.006	p=0.049	r=0.079 p=0.517	p=0.758	r=0.115 p=0.345	p=0.835	r=-0.042 p=0.732	p=0.968
ADAMTS13	r=0.245 p=0.040	p=0.095	r=-0.298 p=0.013	p=0.127	r=-0.236 p=0.051	p=0.290	r=-0.202 p=0.096	p=0.764
ВОС	r=-0.032 p=0.797	p=0.877	r=-0.289 p=0.013	p=0.127	r=0.032 p=0.794	p=0.993	r=-0.193 p=0.113	p=0.764
IL-4RA	r=0.296 p=0.013	p=0.059	r=0.125 p=0.305	p=0.575	r=-0.010 p=0.934	p=0.993	r=0.102 p=0.402	p=0.905

SRC	r=0.072 p=0.558	p=0.686	r=-0.001 p=0.995	p=0.995	r=-0.097 p=0.426	p=0.923	r=-0.069 p=0.575	p=0.943
IL-1RA	r=0.314 p=0.009	p=0.053	r=0.302 p=0.012	p=0.127	r=0.032 p=0.791	p=0.993	r=0.021 p=0.864	p=0.968
IL-6	r=0.346 p=0.004	p=0.045	r=0.263 p=0.029	p=0.175	r=0.270 p=0.025	p=0.245	r=0.025 p=0.840	p=0.968
TNFRSF10A	r=0.243 p=0.044	p=0.154	r=-0.111 p=0.363	p=0.616	r=-0.017 p=0.892	p=0.993	r=0.024 p=0.845	p=0.968
STK4	r=0.126 p=0.303	p=0.437	r=0.041 p=0.739	p=0.896	r=-0.114 p=0.349	p=0.835	r=-0.066 p=0.589	p=0.943
IDUA	r=0.064 p=0.599	p=0.698	r=-0.216 p=0.075	p=0.295	r=-0.116 p=0.344	p=0.835	r=-0.015 p=0.904	p=0.968
TNFRSF11A	r=0.336 p=0.005	p=0.045	r=0.045 p=0.714	p=0.890	r=0.083 p=0.500	p=0.947	r=-0.041 p=0.741	p=0.968
PAR-1	r=0.131 p=0.284	p=0.423	r=0.006 p=0.958	p=0.979	r=-0.025 p=0.839	p=0.993	r=-0.084 p=0.495	p=0.919
TRAIL-R2	r=0.180 p=0.138	p=0.322	r=0.016 p=0.895	p=0.965	r=0.022 p=0.856	p=0.993	r=0.064 p=0.604	p=0.943
PRSS27	r=0.077 p=0.530	p=0.660	r=-0.242 p=0.046	p=0.218	r=-0.084 p=0.492	p=0.947	r=0.036 p=0.769	p=0.968
TIE2	r=0.015 p=0.901	p=0.927	r=-0.123 p=0.316	p=0.575	r=0.063 p=0.609	p=0.955	r=-0.240 p=0.047	p=0.568
TF	r=-0.158 p=0.195	p=0.394	r=-0.223 p=0.065	p=0.281	r=0.003 p=0.981	p=0.993	r=-0.096 p=0.434	p=0.905
IL1RL2	r=0.178 p=0.143	p=0.325	r=-0.243 p=0.045	p=0.218	r=-0.021 p=0.861	p=0.993	r=0.022 p=0.854	p=0.968
PDGF-b	r=-0.131 p=0.283	p=0.423	r=-0.123 p=0.315	p=0.575	r=-0.270 p=0.025	p=0.245	r=-0.220 p=0.049	p=0.568
IL-27	r=0.150 p=0.218	p=0.414	r=-0.020 p=0.868	p=0.955	r=0.066 p=0.587	p=0.949	r=-0.187 p=0.124	p=0.764

IL-17D	r=0.068 p=0.576	p=0.698	r=-0.065 p=0.594	p=0.819	r=-0.023 p=0.852	p=0.993	r=0.024 p=0.847	p=0.968
CXCL1	r=0.333 p=0.005	p=0.045	r=-0.042 p=0.732	p=0.896	r=0.149 p=0.221	p=0.835	r=0.125 p=0.307	p=0.828
Gal-9	r=0.306 p=0.010	p=0.053	r=0.124 p=0.311	p=0.575	r=0.121 p=0.321	p=0.835	r=-0.065 p=0.596	p=0.943
GIF	r=0.283 p=0.018	p=0.078	r=-0.199 p=0.102	p=0.045	r=-0.142 p=0.244	p=0.835	r=-0.350 p=0.003	p=0.273
SCF	r=-0.458 p=0.001	p=0.030	r=-0.414 p<0.001	p=0.032	r=-0.296 p=0.014	p=0.245	r=-0.160 p=0.189	p=0.775
IL-18	r=0.343 p=0.004	p=0.045	r=0.288 p=0.017	p=0.130	r=0.273 p=0.023	p=0.245	r=0.057 p=0.642	p=0.957
FGF21	r=0.255 p=0.035	p=0.094	r=0.177 p=0.145	p=0.402	r=-0.028 p=0.818	p=0.993	r=-0.076 p=0.535	p=0.942
PIgR	r=-0.021 p=0.866	p=0.916	r=-0.156 p=0.201	p=0.481	r=-0.076 p=0.534	p=0.949	r=-0.011 p=0.926	p=0.968
RAGE	r=0.161 p=0.187	p=0.394	r=-0.161 p=0.186	p=0.481	r=-0.020 p=0.870	p=0.993	r=0.119 p=0.332	p=0.828
SOD2	r=0.147 p=0.227	p=0.414	r=-0.171 p=0.159	p=0.425	r=0.174 p=0.153	p=0.696	r=0.092 p=0.451	p=0.912
CTRC	r=0.122 p=0.320	p=0.455	r=0.008 p=0.950	p=0.979	r=0.065 p=0.595	p=0.949	r=0.031 p=0.800	p=0.968
FGF23	r=0.126 p=0.302	p=0.437	r=-0.11 p=0.366	p=0.616	r=-0.072 p=0.556	p=0.949	r=0.009 p=0.941	p=0.973
SPON2	r=0.312 p=0.008	p=0.053	r=-0.096 p=0.431	p=0.676	r=0.003 p=0.980	p=0.993	r=-0.073 p=0.549	p=0.942
GH	r=0.103 p=0.398	p=0.532	r=0.003 p=0.982	p=0.992	r=0.026 p=0.833	p=0.993	r=-0.016 p=0.893	p=0.968
FS	r=0.153 p=0.210	p=0.414	r=-0.193 p=0.112	p=0.339	r=-0.042 p=0.734	p=0.993	r=-0.163 p=0.182	p=0.775

GLO1	r=0.029 p=0.813	p=0.877	r=-0.214 p=0.078	p=0.295	r=0.048 p=0.695	p=0.993	r=-0.155 p=0.203	p=0.775
CD84	r=-0.016 p=0.894	p=0.927	r=-0.177 p=0.145	p=0.402	r=-0.126 p=0.302	p=0.835	r=-0.145 p=0.236	p=0.775
PAPPA	r=0.142 p=0.245	p=0.414	r=-0.113 p=0.357	p=0.616	r=-0.066 p=0.589	p=0.949	r=-0.098 p=0.421	p=0.905
SERPINA12	r=0.014 p=0.910	p=0.927	r=-0.068 p=0.581	p=0.813	r=0.052 p=0.674	p=0.993	r=-0.085 p=0.489	p=0.919
REN	r=0.184 p=0.129	p=0.317	r=-0.279 p=0.020	p=0.130	r=-0.082 p=0.500	p=0.947	r=-0.180 p=0.138	p=0.775
DECR1	r=0.181 p=0.137	p=0.322	r=0.048 p=0.696	p=0.879	r=0.048 p=0.693	p=0.993	r=0.192 p=0.114	p=0.764
MERTK	r=0.143 p=0.241	p=0.414	r=-0.088 p=0.473	p=0.729	r=0.104 p=0.397	p=0.903	r=-0.193 p=0.112	p=0.764
KIM1	r=0.323 p=0.007	p=0.053	r=-0.102 p=0.406	p=0.651	r=0.012 p=0.920	p=0.993	r=-0.151 p=0.215	p=0.775
THBS2	r=0.465 p<0.001	p=0.030	r=0.139 p=0.254	p=0.550	r=0.002 p=0.990	p=0.993	r=-0.117 p=0.337	p=0.828
TM	r=0.244 p=0.043	p=0.154	r=0.055 p=0.625	p=0.825	r=-0.013 p=0.913	p=0.993	r=-0.062 p=0.612	p=0.943
VSIG2	r=0.166 p=0.172	p=0.372	r=-0.026 p=0.835	p=0.938	r=-0.092 p=0.454	p=0.947	r=-0.151 p=0.215	p=0.775
AMBP	r=0.131 p=0.284	p=0.423	r=-0.159 p=0.192	p=0.481	r=-0.119 p=0.332	p=0.835	r=-0.155 p=0.205	p=0.775
PRELP	r=0.013 p=0.917	p=0.927	r=-0.293 p=0.014	p=0.127	r=-0.135 p=0.269	p=0.835	r=-0.082 p=0.505	p=0.919
НО-1	r=0.081 p=0.799	p=0.877	r=-0.062 p=0.612	p=0.825	r=0.304 p=0.011	p=0.245	r=-0.167 p=0.169	p=0.775
XCL1	r=0.237 p=0.050	p=0.156	r=0.131 p=0.283	p=0.574	r=0.117 p=0.336	p=0.835	r=0.000 p=0.999	p=0.999

IL-16	r=0.141 p=0.246	p=0.414	r=0.133 p=0.277	p=0.574	r=0.265 p=0.027	p=0.245	r=0.325 p=0.007	p=0.273
SORT1	r=0.004 p=0.977	p=0.977	r=-0.068 p=0.581	p=0.813	r=-0.144 p=0.237	p=0.835	r=-0.118 p=0.336	p=0.828
CEACAM8	r=0.218 p=0.072	p=0.204	r=0.149 p=0.220	p=0.500	r=0.001 p=0.993	p=0.993	r=0.057 p=0.641	p=0.957
PTX3	r=0.274 p=0.061	p=0.185	r=0.249 p=0.039	p=0.208	r=-0.067 p=0.582	p=0.949	r=0.070 p=0.570	p=0.943
PSGL-1	r=0.138 p=0.257	p=0.423	r=-0.204 p=0.094	p=0.305	r=0.129 p=0.289	p=0.835	r=-0.038 p=0.759	p=0.968
CCL17	r=0.100 p=0.412	p=0.543	r=-0.059 p=0.629	p=0.825	r=0.163 p=0.181	p=0.784	r=0.314 p=0.009	p=0.273
CCL3	r=0.146 p=0.231	p=0.414	r=0.367 p=0.002	p=0.060	r=0.054 p=0.658	p=0.993	r=-0.086 p=0.484	p=0.919
MMP7	r=0.207 p=0.088	p=0.235	r=-0.125 p=0.305	p=0.575	r=0.126 p=0.301	p=0.835	r=-0.014 p=0.908	p=0.968
IgG FgR IIb	r=0.090 p=0.460	p=0.581	r=-0.072 p=0.552	p=0.797	r=0.034 p=0.780	p=0.993	r=0.016 p=0.893	p=0.968
ITGB1BP2	r=0.297 p=0.013	p=0.059	r=0.217 p=0.074	p=0.295	r=0.244 p=0.044	p=0.279	r=0.025 p=0.841	p=0.968
DCN	r=0.222 p=0.066	p=0.193	r=-0.145 p=0.234	p=0.519	r=0.007 p=0.955	p=0.993	r=-0.127 p=0.300	p=0.828
Dkk-1	r=0.065 p=0.597	p=0.698	r=-0.206 p=0.089	p=0.305	r=-0.019 p=0.880	p=0.993	r=-0.143 p=0.242	p=0.775
LPL	r=-0.290 p=0.012	p=0.049	r=-0.294 p=0.013	p=0.127	r=-0.284 p=0.018	p=0.245	r=-0.084 p=0.493	p=0.919
PRSS8	r=0.054 p=0.661	p=0.761	r=-0.102 p=0.405	p=0.651	r=-0.252 p=0.037	p=0.279	r=-0.144 p=0.239	p=0.775
AGRP	r=0.230 p=0.040	p=0.151	r=0.152 p=0.211	p=0.492	r=0.128 p=0.296	p=0.835	r=0.046 p=0.912	p=0.968

HB-EGF	r=0.137 p=0.262	p=0.423	r=-0.282 p=0.019	p=0.130	r=-0.083 p=0.496	p=0.947	r=-0.118 p=0.333	p=0.828
GDF-2	r=-0.029 p=0.810	p=0.877	r=-0.177 p=0.146	p=0.402	r=-0.002 p=0.987	p=0.993	r=-0.075 p=0.543	p=0.942
FABP2	r=-0.111 p=0.364	p=0.494	r=-0.084 p=0.494	p=0.739	r=0.013 p=0.915	p=0.993	r=-0.141 p=0.247	p=0.775
THPO	r=-0.202 p=0.095	p=0.247	r=-0.393 p<0.001	p=0.045	r=-0.088 p=0.470	p=0.947	r=-0.124 p=0.309	p=0.828
MARCO	r=0.145 p=0.236	p=0.414	r=-0.031 p=0.801	p=0.911	r=0.217 p=0.074	p=0.396	r=-0.049 p=0.691	p=0.968
GT	r=0.159 p=0.191	p=0.394	r=0.015 p=0.902	p=0.965	r=0.046 p=0.705	p=0.993	r=0.163 p=0.181	p=0.775
BNP	r=0.135 p=0.270	p=0.423	r=0.118 p=0.336	p=0.599	r=-0.138 p=0.259	p=0.835	r=0.095 p=0.438	p=0.905
MMP12	r=0.352 p=0.003	p=0.045	r=0.346 p=0.004	p=0.072	r=0.328 p=0.006	p=0.245	r=0.237 p=0.050	p=0.568
ACE2	r=0.047 p=0.704	p=0.800	r=-0.007 p=0.955	p=0.979	r=-0.117 p=0.340	p=0.835	r=-0.050 p=0.681	p=0.968
PD-L2	r=0.148 p=0.226	p=0.414	r=-0.035 p=0.777	p=0.906	r=0.072 p=0.559	p=0.949	r=-0.001 p=0.991	p=0.999
CSTL1	r=0.232 p=0.050	p=0.156	r=-0.038 p=0.777	p=0.906	r=0.099 p=0.418	p=0.923	r=0.010 p=0.990	p=0.968
hOSCAR	r=0.361 p=0.002	p=0.036	r=0.250 p=0.038	p=0.208	r=0.241 p=0.046	p=0.279	r=0.236 p=0.033	p=0.568
TNFRSF13B	r=0.362 p=0.002	p=0.036	r=0.039 p=0.750	p=0.898	r=0.069 p=0.576	p=0.949	r=-0.051 p=0.677	p=0.968
TGM2	r=0.028 p=0.820	p=0.877	r=-0.208 p=0.086	p=0.305	r=-0.042 p=0.734	p=0.993	r=-0.273 p=0.023	p=0.523
LEP	r=-0.117 p=0.339	p=0.474	r=-0.131 p=0.284	p=0.574	r=-0.269 p=0.020	p=0.245	r=-0.142 p=0.244	p=0.775

CA5A	r=0.098 p=0.424	p=0.551	r=-0.053 p=0.664	p=0.851	r=-0.185 p=0.127	p=0.608	r=-0.138 p=0.257	p=0.779
HSP27	r=0.186 p=0.127	p=0.317	r=0.058 p=0.635	p=0.825	r=0.020 p=0.867	p=0.993	r=-0.037 p=0.761	p=0.968
CD4	r=0.343 p=0.001	p=0.030	r=0.083 p=0.496	p=0.739	r=0.246 p=0.042	p=0.279	r=0.012 p=0.924	p=0.968
NEMO	r=0.131 p=0.284	p=0.423	r=-0.020 p=0.871	p=0.955	r=-0.033 p=0.787	p=0.993	r=0.103 p=0.399	p=0.905
VEGFD	r=0.115 p=0.348	p=0.479	r=-0.351 p=0.003	p=0.068	r=-0.204 p=0.092	p=0.465	r=-0.110 p=0.368	p=0.881
PARP-1	r=0.237 p=0.050	p=0.156	r=0.011 p=0.930	p=0.979	r=0.010 p=0.935	p=0.993	r=0.100 p=0.415	p=0.905
HAOX1	r=0.067 p=0.583	p=0.698	r=0.101 p=0.408	p=0.651	r=-0.126 p=0.304	p=0.835	r=0.033 p=0.788	p=0.968

Supplementary Table 9: List of proteins associated with IgG or IgM anti-HDL antibodies in RA. Serum proteins found to be associated with IgG (n=23) or IgM (n=5) anti-HDL antibodies are listed along with their KEGG ortholog codes and most representative functions.

	Protein	KEGG ortholog	Functions		
	SCF	K05461	Cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function		
	THBS2	K04659	Mediates cell-to-cell and cell-to-matrix interactions. Ligand for CD36 mediating antiangiogenic properties		
	CD4	K06454	Immune activation		
	hOSCAR	K14377	Osteoclastogenesis, remodelling		
	TNFRSF13B	K05150	Stimulation of B- and T-cell function and the regulation of humoral immunity		
	MMP12	K01413	Extracellular matrix remodelling		
	IL-6	K05405	Immune activation		
Anti-HDL IgG	IL-18	K10030	Immune activation		
	TNFRSF11A	K05147	Osteoclastogenesis, remodelling, interactions between T-cells and dendritic cells		
	CXCL1	K05505	Neutrophil activation and migration; endothelial activation		
	PGF	K16859	Angiogenesis and endothelial cell growth, stimulating their proliferation and migration		
	KIM1	K20413	T-helper cell development and the regulation of asthma and allergic diseases Kidney injury and repair		
	SPON2	K24428	Cell adhesion Opsonization Innate immune response, LPS-R Extracellular matrix homeostasis		

	IL-1RA	K05071	Immune regulation			
	ANGPT1	K05465	Regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence Vascular homeostasis			
	Gal-9	K10093	Inhibition angiogenesis Th1/Th2 polarization			
	SLAMF7	K06733	Regulation and interconnection of both innate and adaptive immune response			
	LPL	K01059	Triglyceride and TRL metabolism Lipid clearance			
	IL-4RA	K05071	Immune regulation			
	ITGB1BP2	K16735	Maturation and differentiation of muscle cells			
	CBLIF	K14615	Vitamin digestion and absorption			
	FGF21	K22429	Glucose metabolism Adipose tissue homeostasis			
	ADAMTS13	K08627	vWF production Extracellular matrix homeostasis			
	SCF	K05461	Cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function			
	ТНРО	K06854	Proliferation and maturation of megakaryocytes from their committed progenitor cells. Major physiological regulator of circulating platelets			
Anti-HDL IgM	CCL3	K05408	Monocyte chemotaxis			
	VEGFD	K05449	Angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration, and also has effects on the permeability of blood vessels Vascular homeostasis			
	MMP12	K01413	Extracellular matrix remodeling			

Supplementary Table 10: List of candidate transcription factors for the proteins analyzed. Transcription factors identified to be common for the proteins analyzed using the TRRUST database.

Abbreviation	Transcription factor	# overlapped genes	p-value	FDR
RELA	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	6	9.41·10 ⁻⁷	8.47·10 ⁻⁶
NFKB1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	5	2.17·10 ⁻⁵	9.77·10 ⁻⁵
STAT3	signal transducer and activator of transcription 3 (acute-phase response factor)	3	0.0005	0.0016
ATF4	activating transcription factor 4 (tax-responsive enhancer element B67)	2	0.0007	0.0016
PPARA	peroxisome proliferator- activated receptor alpha	2	0.0009	0.0016
SPI1	spleen focus forming virus (SFFV) proviral integration oncogene spi1	2	0.0023	0.0035
CREB1	cAMP responsive element binding protein 1	2	0.0048	0.0062
JUN	jun proto-oncogene	2	0.0129	0.0145
SP1	Sp1 transcription factor	3	0.0168	0.0168

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure 1: Levels of antibodies against HDL particles in clinical RA. Levels of IgG anti-HDL and anti-ApoA1 (both IgG and IgM) in early RA (RA) and established, long-lasting RA (LRA) are shown. Bars represent 25th percentile (lower), median and 75th percentile (upper). Differences were assessed by Mann-Withney U tests.

Supplementary Figure 2: PON1 activity across study groups. Levels PON1 enzymatic activity (U) in HC, CSA individuals and early RA patients are shown. Bars represent 25th percentile (lower), median and 75th percentile (upper). Differences were assessed by Kruskal-Wallis tests with Dunn-Bonferroni post-hoc tests. The p-values from the latter were indicated as follows: * p<0.050, and *** p<0.001.

Supplementary Figure 3: Network analyses of proteomic signatures and atherosclerosis status. The interactions among proteins found to be associated with IgG anti-HDL levels were depicted in networks for patients without atherosclerosis (n=31) and with atherosclerosis (n=46). Each node corresponds to a protein and the lines between nodes illustrate the strength (width) and type (red: positive, blue: negative) of the correlations between each pair of nodes. The relative position of the nodes parallels its degree of correlation, that is, nodes more closely correlated locate closer to each other.